136 related articles for article (PubMed ID: 18493873)
1. Prolonged survival using anti-CD20 combined chemotherapy in primary prostatic intravascular large B-cell lymphoma.
Csomor J; Kaszás I; Kollár B; Pajor L; Egyházi Z; Fekete S; Egyed M; Timár B
Pathol Oncol Res; 2008 Sep; 14(3):281-4. PubMed ID: 18493873
[TBL] [Abstract][Full Text] [Related]
2. Ifosfamide, epirubicin and etoposide rituximab in refractory or relapsed B-cell lymphoma: analysis of remission induction and stem cell mobilization.
Menzel H; Müller A; Von Schilling C; Licht T; Peschel C; Keller U
Leuk Lymphoma; 2008 Jul; 49(7):1337-44. PubMed ID: 18604723
[TBL] [Abstract][Full Text] [Related]
3. Prostate involvement by intravascular large B-cell lymphoma: a case report with literature review.
Xu M; Yang Q; Li M; Geng W; Huang W; Chen Y
Int J Surg Pathol; 2011 Aug; 19(4):544-7. PubMed ID: 21632638
[TBL] [Abstract][Full Text] [Related]
4. Transformation of Hodgkin's disease to high-grade B-cell lymphoma: remission after Rituximab monotherapy.
Kirchner EM; Ebsen M; Kirchner J; Theegarten D; Voigtmann R
Ann Oncol; 2001 Aug; 12(8):1169-71. PubMed ID: 11583202
[TBL] [Abstract][Full Text] [Related]
5. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Griffin TC; Weitzman S; Weinstein H; Chang M; Cairo M; Hutchison R; Shiramizu B; Wiley J; Woods D; Barnich M; Gross TG;
Pediatr Blood Cancer; 2009 Feb; 52(2):177-81. PubMed ID: 18816698
[TBL] [Abstract][Full Text] [Related]
6. Intravascular large B-Cell lymphoma with bone marrow involvement and superior sagittal sinus thrombosis: report of a case successfully treated with a CHOP/rituximab combination regimen.
Jardin F; Callonnec F; Contentin N; Picquenot JM; Gueit I; Héron F; Bastard C; Tilly H
Clin Lymphoma; 2005 Jun; 6(1):46-9. PubMed ID: 15989707
[TBL] [Abstract][Full Text] [Related]
7. Histological analysis on adhesive molecules of renal intravascular large B cell lymphoma treated with CHOP chemotherapy and rituximab.
Kusaba T; Hatta T; Tanda S; Kameyama H; Tamagaki K; Okigaki M; Inaba T; Shimazaki C; Sasaki S
Clin Nephrol; 2006 Mar; 65(3):222-6. PubMed ID: 16550755
[TBL] [Abstract][Full Text] [Related]
8. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study.
Hagberg H; Gisselbrecht C;
Ann Oncol; 2006 May; 17 Suppl 4():iv31-2. PubMed ID: 16702182
[TBL] [Abstract][Full Text] [Related]
9. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
[TBL] [Abstract][Full Text] [Related]
10. [Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy].
Iguchi T; Miyazawa K; Okabe S; Kawakubo K; Shimamoto T; Kuriyama Y; Ito Y; Kimura Y; Ohyashiki K; Serizawa H; Iwaya K; Mukai K
Rinsho Ketsueki; 2004 Oct; 45(10):1129-34. PubMed ID: 15553050
[TBL] [Abstract][Full Text] [Related]
11. [Cutaneous B-cell lymphoma treatment with rituximab: two cases].
Viguier M; Bachelez H; Brice P; Rivet J; Dubertret L
Ann Dermatol Venereol; 2002 Oct; 129(10 Pt 1):1152-5. PubMed ID: 12442128
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of diffuse large B-cell lymphoma following Waldenström's macroglobulinemia with CHOP chemotherapy followed by combination therapy of CHOP with rituximab.
Uchino K; Sameshima H; Miyamoto T; Iino T; Kato K; Henzan H; Aoki K; Nagafuji K; Gondo H; Harada M
Intern Med; 2004 Feb; 43(2):131-4. PubMed ID: 15005256
[TBL] [Abstract][Full Text] [Related]
13. Anthracyline-reduced sequential combination chemotherapy for younger patients with good-prognosis aggressive B-cell non-Hodgkin's lymphoma.
Schütt P; Zimmermann K; Derks C; Ebeling P; Welt A; Poser M; Hense J; Metz K; Anhuf J; Sandmann M; Neise M; Moritz T; Stuschke M; Niederle N; Seeber S; Nowrousian MR
J Cancer Res Clin Oncol; 2009 Mar; 135(3):459-66. PubMed ID: 18758815
[TBL] [Abstract][Full Text] [Related]
14. A phase I-II study of rituximab, ifosfamide, mitoxantrone and etoposide (R-IME) for B cell non-Hodgkin's lymphoma prior to and after high-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT).
Joyce RM; Regan M; Ottaway J; Umiel T; Tetreault JC; Levine J; McDermott D; Hurley D; Giallombardo N; Smith T; Lamontagne D; Uhl L; Avigan D
Ann Oncol; 2003; 14 Suppl 1():i21-7. PubMed ID: 12736227
[TBL] [Abstract][Full Text] [Related]
15. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
16. [A case of malignant lymphoma associated with diffuse pulmonary involvement successfully treated with rituximab].
Kataoka T; Ishida Y; Kurokawa R; Takeshita S; Ohta K; Nishimura Y; Yokoyama M
Nihon Kokyuki Gakkai Zasshi; 2003 Dec; 41(12):899-904. PubMed ID: 14727553
[TBL] [Abstract][Full Text] [Related]
17. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study.
Jermann M; Jost LM; Taverna Ch; Jacky E; Honegger HP; Betticher DC; Egli F; Kroner T; Stahel RA
Ann Oncol; 2004 Mar; 15(3):511-6. PubMed ID: 14998858
[TBL] [Abstract][Full Text] [Related]
18. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).
Pfreundschuh M; Schubert J; Ziepert M; Schmits R; Mohren M; Lengfelder E; Reiser M; Nickenig C; Clemens M; Peter N; Bokemeyer C; Eimermacher H; Ho A; Hoffmann M; Mertelsmann R; Trümper L; Balleisen L; Liersch R; Metzner B; Hartmann F; Glass B; Poeschel V; Schmitz N; Ruebe C; Feller AC; Loeffler M;
Lancet Oncol; 2008 Feb; 9(2):105-16. PubMed ID: 18226581
[TBL] [Abstract][Full Text] [Related]
19. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
[TBL] [Abstract][Full Text] [Related]
20. Rituximab in combination with CODOX-M/IVAC: a retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%.
Mohamedbhai SG; Sibson K; Marafioti T; Kayani I; Lowry L; Goldstone AH; Linch DC; Ardeshna KM
Br J Haematol; 2011 Jan; 152(2):175-81. PubMed ID: 21092025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
